NICE greenlights RoActemra, snubs Afinitor

The U.K.'s cost-effectiveness watchdog changed its mind to recommend Roche's arthritis drug RoActemra for use by the National Health Service, but it rejected the use of Novartis' Afinitor in patients with kidney cancer. Report | Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.